- Efficacy and Safety of Atorvastatin as Adjunctive Treatment
- 2 in Chronic Obstructive Pulmonary Disease: A Systematic
- Review and Meta-Analysis

4	Ke Chen ¹⁴⁵ , <u>chenke111718@163.com</u>													
5	Bowen Xu ¹⁴⁵ , <u>1304520495@qq.com</u>													
6	Lu Zhang ²⁴⁵ ,18715028922@163.com													
7	Li Fang ¹⁴⁵ , fangli 0825@163.com													
8	Di <u>Wu³⁴⁵</u> , <u>1293603638@qq.com</u>													
9	Huanzhang Ding ¹⁴⁵ ,598620653@qq.com													
10	Zegeng <u>Li¹²⁴⁵*,15056765167@163.com</u>													
11	¹ The First Clinical Medical College of Anhui University of Chinese													
12	Medicine,Hefei,230031,China													
13	² Anhui University of Chinese Medicine,Hefei,230012,China													
14	³ Anhui Provincial Chinese Medicine Hospital, Hefei, 230031, China													
15	⁴ Institute of Traditional Chinese Medicine for Respiratory Disease Prevention and													
16	Treatment, Anhui Academy of Traditional Chinese Medicine, Hefei, 230031													
17	⁵ Anhui Provincial Key Laboratory of Translational Medicine for Prevention and													
18	Treatment of Major Respiratory Diseases with Traditional Chinese Medicine, Hefei,													
19	230031													
20	Corresponding Author :Zegeng Li email: 15056765167@163.com													
21	Affiliation: Anhui Provincial Chinese Medicine Hospital													

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Background:Accumulating evidence suggests that atorvastatin, a widely used lipid-lowering agent, may provide additional benefits for chronic obstructive pulmonary disease (COPD) patients, including anti-inflammatory effects and improved lung function. However, inconsistent findings across studies warrant a systematic evaluation to clarify its clinical role. Objective: To systematically evaluate the efficacy and safety of atorvastatin as an adjunctive treatment for COPD and inform clinical decision-making. Methods: A comprehensive search of PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang, CBM, and VIP databases identified randomized controlled trials (RCTs) up to May 20, 2024. Meta-analysis using RevMan 5.3 and R software was performed to estimate pooled effects with mean differences or standardized mean differences (95% CI). Subgroup analyses explored variations by treatment duration and dosage. **Results:**Twenty-four RCTs involving 2,534 patients demonstrated significant benefits of atorvastatin for stable COPD and acute exacerbations (AECOPD):Lung function: FEV1%pred increased by 5.36% (95% CI: 4.57–6.14), FEV1/FVC by 6.30% (95% CI: 4.46-8.14), and FEV1 by 0.21 L (95% CI: 0.15-0.27). Inflammatory markers: CRP decreased by 1.87 mg/L (95% CI: 1.45-2.29), with reductions in hs-CRP and IL-6.Quality of life: CAT scores improved by 3.5 points (95% CI: 2.8–4.2). Exercise capacity: The 6-minute walk distance increased by 25.4 meters (95% CI: 18.1-32.7). Stronger evidence emerged with 3-month treatments ($I^2 < 30\%$) and consistent benefits at 20 mg doses. Adverse events were mild and self-limiting. Conclusion: Atorvastatin (20 mg) significantly improves lung function, reduces inflammation, and enhances quality of life in COPD patients, with a favorable safety profile. Although not currently recommended in COPD guidelines, these findings

support further trials to validate its potential role in COPD management.

Key words: Atorvastatin, chronic obstructive pulmonary, Meta-analysis, RCT

1. Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent global public health concern characterized by airflow limitation and chronic airway inflammation[1]. According to data from the World Health Organization, COPD is among the leading causes of mortality globally. Epidemiological studies indicate that the global prevalence of COPD among adults aged 40 and above is approximately $9\% \sim 10\%[2]$. COPD detrimentally affects patients' quality of life and imposes a substantial economic burden on healthcare systems[3;4] Although bronchodilators and corticosteroids are commonly utilized in COPD management, their efficacy remains suboptimal in certain patient populations[5]. Recent years have seen the emergence of statins, particularly atorvastatin and simvastatin, as promising agents in the treatment of COPD. Research suggests that atorvastatin may enhance lung function, inhibit inflammatory responses, and reduce oxidative stress in COPD patients while also exhibiting favorable safety profiles[6;7]. Consequently, this study systematically assesses the efficacy and safety of atorvastatin as an adjunctive treatment for COPD. aiming to furnish clinicians with enhanced evidence-based support. Furthermore, it conducts subgroup analyses stratified by dosage, treatment duration, and disease severity, with the goal of providing robust data to inform clinical decision-making.

2.Methods

2.1. Protocol and Registration

70 This meta-analysis was conducted in accordance with the Preferred Reporting Items

for Systematic Reviews and Meta-Analyses (PRISMA) guidelines(see

Supplementary Document 1). The protocol for this study was registered in the

International Prospective Register of Systematic Reviews (PROSPERO) under

registration number CRD42024531466.

2.2 Search Strategy and Inclusion Criteria

75

76 A comprehensive search of relevant studies was conducted across eight major databases: PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang 77 Data, CBM, and VIP. The search spanned from the inception of each database to May 78 20, 2024. To ensure the search captured all relevant studies, we used a combination of 79 Medical Subject Headings (MeSH) and free-text terms, such as "Chronic Obstructive 80 Pulmonary Disease," "atorvastatin," "inflammation," and "lung function." Boolean 81 operators (AND, OR) were applied, and search terms were tailored to each database. 82 We also conducted supplementary searches, including reference lists of relevant 83 articles and systematic reviews, to identify additional eligible studies. 84 Studies were eligible for inclusion if they were randomized controlled trials (RCTs) 85 evaluating atorvastatin as an adjunctive treatment in patients diagnosed with chronic 86 obstructive pulmonary disease (COPD) based on established criteria, such as the 87 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines[8]. To 88 ensure clinical relevance, included studies needed to report at least one of the 89 90 following outcomes: (1) primary outcomes—lung function parameters (e.g., FEV1%pred, FEV1/FVC) and systemic inflammatory markers (e.g., CRP, hs-CRP, 91 92 IL-6); or (2) secondary outcomes—exercise capacity (e.g., 6-minute walk distance),

quality of life (e.g., COPD Assessment Test [CAT]), or adverse events.Interventions were considered eligible if atorvastatin was compared to placebo or standard COPD treatment.

Studies were excluded if they were non-randomized trials, observational studies, case reports, or reviews. Additionally, we excluded studies with insufficient data for analysis, animal models, or those involving atorvastatin doses outside the clinical guidelines. Full-text articles not available in English or Chinese were also excluded to ensure accurate data interpretation.

2.3.Data Extraction and Quality Assessment

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Data extraction was independently conducted by two reviewers, Ke Chen and Bowen Xu, using a standardized data extraction form to ensure consistency and accuracy. The information extracted included study characteristics, such as author names, publication year, country, and sample size, as well as participant demographics, including age, sex, Chronic Obstructive Pulmonary Disease (COPD) severity, and comorbidities. Details of the interventions, including atorvastatin dosage, treatment duration, and comparator interventions, were also collected. The primary outcomes of interest were lung function parameters, specifically the Forced Expiratory Volume in the first second as a percentage of the predicted value (FEV1%pred) and the Forced Expiratory Volume in the first second to Forced Vital Capacity ratio (FEV1/FVC). Additionally, inflammatory markers, such as C-reactive protein high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6), were included as primary outcomes. Secondary outcomes encompassed exercise capacity, measured

by the six-minute walk distance (6MWD), quality of life, assessed using the COPD Assessment Test (CAT), and adverse events, including elevated alanine aminotransferase (ALT) levels and myopathy. Any disagreements arising during the data extraction process were resolved through discussion or, when necessary, consultation with a third reviewer, Huanzhang Ding, to ensure the reliability of the extracted data.

The quality of included studies was assessed using the Cochrane RoB 2 tool[9], which evaluates five domains: randomization process, deviations from intended

interventions, missing outcome data, measurement of outcomes, and selection of reported results. Each domain was rated as "low risk," "some concerns," or "high risk," and overall bias for each study was determined. Two reviewers conducted the risk of bias assessment independently, with discrepancies resolved by consensus. This

systematic approach ensured the reliability and validity of the included studies for

subsequent meta-analysis.

2.4.Data Synthesis and Statistical Analysis

All statistical analyses were performed using RevMan 5.3 and R (v3.6.1). Continuous outcomes (e.g., lung function parameters, inflammatory markers, and quality of life scores) were summarized as mean differences (MD) or standardized mean differences (SMD) with corresponding 95% confidence intervals (CI). Dichotomous outcomes (e.g., adverse events) were analyzed using risk ratios (RR) with 95% CI. The pooled effect size for each outcome was calculated using either a fixed-effect model or a random-effects model, depending on the degree of heterogeneity observed.

Heterogeneity was assessed using the I² statistic and τ^2 values. An I² > 50% was considered indicative of substantial heterogeneity, prompting the use of a random-effects model to account for variability among studies. For outcomes with low heterogeneity ($I^2 < 50\%$), a fixed-effect model was employed. Additionally, the Cochran Q test (p < 0.10) was used to further evaluate statistical heterogeneity. Sensitivity analyses were conducted to assess the robustness of the pooled results by excluding high-risk studies (e.g., those rated as "Some Concerns" or "High Risk" in the Cochrane RoB 2 tool) and by re-analyzing data using alternative statistical models. Subgroup analyses were pre-specified to explore potential sources of heterogeneity. Stratifications were performed based on atorvastatin dosage (20 mg vs. 40 mg), treatment duration (<6 months vs. ≥6 months), and patient condition (stable COPD vs. acute exacerbation of COPD [AECOPD]). Publication bias was evaluated using funnel plots and Egger's regression test, provided that the number of included studies exceeded 10, as smaller samples may yield unreliable assessments. Visual inspection of funnel plot symmetry was used to detect potential small-study effects. In cases where asymmetry was observed, additional analyses were conducted to explore its impact on the overall meta-analytic results. Statistical significance was set at p < 0.05 for all analyses, except where otherwise specified.

3. Results

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

3.1.Literature Screening Process and Results

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

A total of 1,100 articles were initially identified. After sequential screening, 24 randomized controlled trials (RCTs)[10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33], were finally included, involving 2,534 patients with chronic obstructive pulmonary disease (COPD). The literature screening process and results are shown in Figure 1. 3.2. Basic Characteristics of Included Studies This meta-analysis included 24 randomized controlled trials (RCTs)¹⁰⁻³⁴published between 2011 and 2024, involving diverse study designs and patient populations. All studies evaluated the efficacy and safety of atorvastatin as an adjunctive treatment for chronic obstructive pulmonary disease (COPD). The sample sizes ranged from 30 to 200 participants per study, with treatment durations varying between 3 to 12 months. The included studies reported key outcomes such as lung function parameters, inflammatory markers, quality of life, and exercise capacity. 3.3. Risk of Bias Assessment The risk of bias for the included studies was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool. The results are summarized as follows:(1)Randomization **Process**: Among the 24 included studies, 20 (83.3%) were evaluated as having a low risk of bias, and 4 (16.7%) had some concerns. None of the studies were assessed as high risk in this domain.(2)Deviations from Intended Interventions: A total of 18 studies (75%) were assessed as having a low risk of bias, and 6 studies (25%) had some concerns. No studies fell into the high-risk category.(3)Missing Outcome Data: In this domain, 15 studies (62.5%) were categorized as low risk, while 9 studies

(37.5%) had some concerns. Again, no high-risk assessments were noted.(4)**Measurement of the Outcome**: For this domain, 12 studies (50%) were rated as low risk, while the remaining 12 studies (50%) had some concerns. None of the studies were deemed high risk.(5)**Selection of the Reported Result**: A total of 24 studies (100%) had some concerns in this domain. No studies were classified as low or high risk.(6)**Overall Bias**:Out of the 24 studies, 24 (100%) were categorized as having some concerns overall. There were no studies classified as low or high risk.

3.4. Results: Meta-Analysis Results

3.4.1. FEV1%pred

A total of 8 RCTs[10; 11; 12; 15; 20; 21; 24; 29; 31] involving 695 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with 20 mg of atorvastatin could improve FEV1%pred. Subgroup analysis based on the treatment duration revealed that the therapy was effective at both 3 months [MD = 5.04, 95% CI (3.92, 6.16), P < 0.00001] and 6 months [MD = 6.53, 95% CI (3.56, 9.51), P < 0.00001]. Subgroup analysis based on different disease states showed that atorvastatin improved FEV1%pred in both AECOPD patients [MD = 5.59, 95% CI (3.95, 7.23), P < 0.00001] and stable patients [MD = 5.47, 95% CI (3.74, 7.19), P < 0.00001]. (Figure 3a)

3.4.2. FEV1/FVC

A total of 9 RCTs⁻[10; 11; 12; 15; 19; 20; 21; 23; 24; 31] involving 882 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with 20 mg of atorvastatin could improve FEV1/FVC. Subgroup

perpetuity.

It is made available under a CC-BY 4.0 International license.

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

analysis based on the treatment duration indicated that the therapy was effective at both 3 months [MD = 6.19, 95% CI (0.9, 11.48), P < 0.00001] and 6 months [MD = 5.08, 95% CI (2.91, 7.26), P < 0.00001]. Subgroup analysis based on different disease states showed that atorvastatin was effective in improving FEV1/FVC in both acute exacerbation patients [MD = 3.63, 95% CI (2.52, 4.74), P < 0.00001] and stable patients [MD = 7.89, 95% CI (1.79, 13.99), P < 0.00001].(Figure 3b) 3.4.3. FEV1 A total of 9 RCTs[10; 11; 12; 15; 19; 20; 21; 24; 29; 31] nvolving 816 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with 20 mg of atorvastatin could improve FEV1. Subgroup analysis based on the treatment duration indicated that the therapy was effective at 3 months [MD = 5.04, 95% CI (3.92, 6.16), P < 0.00001] and also effective at 6 months [MD = 6.53, 95% CI (3.56, 9.51), P < 0.00001]. Subgroup analysis based on different disease states showed that atorvastatin was effective in improving FEV1 in both acute exacerbation and remission stages of COPD patients. Subgroup analysis based on different dosages revealed that only the 20 mg dose of atorvastatin was effective in improving FEV1 in COPD patients.(Figure 3c) 3.4.4. CRP A total of 4 RCTs[16;18,25,32]involving 334 patients were included. CRP Levels Subgroup analysis demonstrated that atorvastatin significantly reduced CRP levels across different doses and treatment durations. A 20 mg dose resulted in an average reduction of 1.87 mg/L (95% CI: 1.45–2.29), while a 40 mg dose further reduced CRP

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

by 2.10 mg/L (95% CI: 1.60-2.60). For every 10 mg increase in dosage, CRP levels decreased by approximately 0.12 mg/L. Regarding treatment duration, significant reductions were observed over both 3 months (-1.50 mg/L, 95% CI: -1.10 to -1.90) and 6 months (-2.30 mg/L, 95% CI: -1.80 to -2.80), with longer durations showing enhanced anti-inflammatory effects. (Figure 4a) 3.4.5. hs-CRP A total of 4 RCTs[15; 21; 26; 27] i involving 269 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with atorvastatin could reduce hs-CRP levels. Subgroup analysis based on different dosages revealed that only the 20 mg dose of atorvastatin was effective in improving hs-CRP levels in COPD patients. Subgroup analysis based on different disease states indicated that atorvastatin improved hs-CRP levels in both AECOPD and COPD patients.(Figure 4b) 3.4.6. IL-6 A total of 5 RCTs[10; 13;27;25,32;] involving 359 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with atorvastatin could reduce IL-6 levels. Subgroup analysis based on different treatment durations indicated that atorvastatin was effective in patients with a treatment duration of up to 6 months but was ineffective in those with a treatment duration of 6 to 12 months. Subgroup analysis based on different dosages revealed that a 20 mg dose of atorvastatin was effective in improving IL-6 levels in COPD patients. (Figure 4c)

3.4.7. CAT Score A total of 7 RCTs[10; 14; 22; 25; 26; 32; 33] involving 639 patients were included. The results of the meta-analysis using a random-effects model showed that adjunctive therapy with atorvastatin could improve CAT scores in COPD patients. Subgroup analysis based on different dosages revealed that both 20 mg and 40 mg doses of atorvastatin could improve CAT scores in COPD patients. Subgroup analysis based on different treatment durations (3, 6, and 12 months) indicated that atorvastatin was effective across short, medium, and long treatment periods. (Figure 5a) 3.4.8. 6MW A total of 6 RCTs[14;19;17; 26;28, 32]involving 715 COPD patients were included. Atorvastatin significantly improved exercise capacity as measured by 6MWD, with subgroup analyses indicating differences based on dosage and treatment duration. Patients treated with a 20 mg dose experienced an average improvement of 25.4 m (95% CI: 18.1–32.7), whereas those receiving a 40 mg dose showed a smaller improvement of 18.0 m (95% CI: 10.0–26.0), possibly reflecting diminished tolerability or adverse effects at higher doses. Treatment duration also played a crucial role, with 6-month treatments yielding a larger improvement of 30.2 m (95% CI: 25.0-35.4) compared to 3-month treatments (18.5 m, 95% CI: 10.2-26.8). These findings emphasize the importance of sustained treatment and optimal dosing for enhancing physical function in COPD patients. (Figure 5b)

3.4.9.ADR events

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

Among the 24 included studies, 3 RCTs [30, 31, 33] reported adverse reactions,

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

accounting for 7.9% of the total study population. The reported adverse events were primarily mild and included symptoms such as dry mouth, gastrointestinal discomfort, dizziness, and palpitations. One study noted mild elevations in ALT levels, which normalized following the administration of liver-protective medications without the need to discontinue atorvastatin therapy. Due to variations in adverse reaction criteria across studies and the limited number of reported events, only descriptive analyses were performed. Statistical significance between groups could not be established. For detailed data, including incidence rates and patient numbers, please refer to the Supplementary Material TableS2. Notably, while adverse events were generally mild and self-limiting, a higher incidence of gastrointestinal symptoms and liver enzyme elevations was observed with the 40 mg dose compared to the 20 mg dose. This suggests a potential dose-dependent relationship in atorvastatin-related adverse events. However, further studies with larger sample sizes and standardized reporting criteria are needed to confirm these findings and better evaluate the safety profile of atorvastatin in COPD patients. 4. Sensitivity Analysis The sensitivity analysis (Figure S1) confirmed the robustness of the pooled results, as the overall estimates remained within the confidence intervals (CI) of the main analysis after excluding each study. However, certain studies, including Zhengwei (2013)[10], Zhang Rongchang (2015)[25], and Hassan Ghobadi (2014)[26], showed

notable contributions to heterogeneity. Excluding Zhengwei (2013)[10] significantly altered the pooled estimate for FEV1%pred (from 5.36% [95% CI: 4.57–6.14] to 4.78% [95% CI: 3.96–5.60]), likely due to the shorter treatment duration (6 months) and inclusion of AECOPD patients, whose inflammatory responses may differ from those of stable COPD patients. Similarly, Zhang Rongchang (2015)[25], a 12-month study, caused a narrowing of the CI when removed (from 4.57–6.14 to 5.01–5.71), suggesting that treatment duration is a key source of variability. Hassan Ghobadi (2014)[26], with a higher atorvastatin dose (40 mg), contributed to heterogeneity due to differences in dosing regimens and potential pharmacokinetic variations in different populations.

These findings highlight the importance of patient characteristics (e.g., AECOPD vs. stable COPD), treatment duration (<6 months vs. ≥6 months), and dosing regimens (20 mg vs. 40 mg) in influencing the pooled results. Future meta-analyses

5.Heterogeneity and Inconsistency Assessment

impact on treatment outcomes and heterogeneity.

In this meta-analysis, heterogeneity was assessed using I^2 and τ^2 statistics, alongside p-values from the Cochran Q test. Several outcomes exhibited moderate heterogeneity, including CAT Score ($I^2 = 52.4\%$) and 6MW ($I^2 = 51.3\%$), likely attributable to differences in study populations, intervention durations, and measurement methods. For outcomes such as FEV1/FVC ($I^2 = 34.5\%$) and CRP ($I^2 = 41.5\%$), heterogeneity was moderate, and results remained consistent between

should consider stratified analyses based on these factors to better elucidate their

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

fixed-effect and random-effects models, underscoring the robustness of the pooled estimates. The τ^2 values, reflecting between-study variance, were relatively low for most outcomes, further supporting the reliability of the results. Notably, hs-CRP (I² = 48.2%) and IL-6 ($I^2 = 46.3\%$) exhibited slightly higher heterogeneity, potentially reflecting variability in baseline inflammation levels or comorbid conditions among study participants. Detailed heterogeneity metrics are provided in Supplementary Table S3. Subgroup analyses revealed that treatment duration (<6 months vs. ≥6 months) and patient condition (AECOPD vs. stable COPD) contributed to the observed heterogeneity in hs-CRP and IL-6, suggesting that these factors may influence baseline inflammation levels and treatment efficacy. 6.Discussion The management of Chronic Obstructive Pulmonary Disease (COPD) remains a significant challenge due to the lack of therapeutic agents that can reverse key pathological features, such as airway remodeling, emphysema, and vascular abnormalities. This highlights the urgent need for novel therapeutic targets and pharmacological interventions[34-36]. Statins, initially developed as lipid-lowering agents, have demonstrated significant anti-inflammatory and antioxidant effects. Specifically, atorvastatin modulates the guanosine triphosphatase and nuclear factor κΒ (NF-κΒ) pathways, inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8. These effects alleviate lung inflammation and reduce

neutrophil infiltration into the lungs[37-39].

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

Dose-Effect Analysis: 40 mg vs. 20 mg Atorvastatin

Figures 4b and 5b show that the therapeutic contribution of the 40 mg dose is smaller than that of the 20 mg dose, potentially due to smaller sample sizes or differences in study design. However, this difference did not significantly affect the overall effect estimates in the primary analysis, indicating that the current evidence is insufficient to conclude the 40 mg dose is ineffective. The superior efficacy of the 20 mg dose may result from its ability to achieve an optimal balance between anti-inflammatory effects and pulmonary function improvement. Higher doses could lead to suboptimal outcomes due to excessive drug concentrations, which may reduce lung-specific bioavailability. Additionally, atorvastatin's pharmacokinetics may limit its targeted delivery at higher doses[40-41]. Ethnic differences might also contribute to variations in the observed effects. For instance, studies involving the 40 mg dose were predominantly conducted in Caucasian populations, whereas evidence suggests that Asian populations are more sensitive to statins due to genetic polymorphisms affecting CYP2D6, CYP2C, and OATP1B1, resulting in higher systemic drug concentrations and enhanced therapeutic sensitivity[42]. Future studies should validate the efficacy of the 40 mg dose in large-scale randomized controlled trials and conduct subgroup analyses to clarify its mechanisms and identify suitable populations.

Heterogeneity Between COPD and AECOPD Populations

Figure 4b indicates that atorvastatin demonstrated therapeutic benefits in both stable

COPD and AECOPD populations, suggesting its efficacy in both chronic and acute disease states. However, the intensity of therapeutic responses likely differs. In AECOPD patients, atorvastatin appears to exert pronounced short-term effects by suppressing acute inflammatory responses. Conversely, in stable COPD patients, the benefits may be more associated with long-term inflammation reduction and improvements in pulmonary vascular function. Future studies should conduct stratified analyses to further explore the differential responses of COPD and AECOPD populations to interventions. This approach will help optimize atorvastatin use based on individual patient characteristics and disease phases, improving clinical practice. **Safety and Adverse Effects** The safety profile of atorvastatin in this study was favorable, with only a few mild adverse reactions reported, including gastrointestinal symptoms, dizziness, headache, palpitations, insomnia, and transient elevations in transaminases. These adverse effects were either self-limiting or resolved after discontinuation of the drug. This aligns with previous studies, emphasizing atorvastatin's good tolerability in COPD treatment[6; 37-45]. To ensure safe application in clinical practice, liver function monitoring is recommended, particularly for patients receiving higher doses or with pre-existing hepatic conditions. Further research should explore strategies to mitigate adverse effects, such as the combination of atorvastatin with hepatoprotective agents.

Comparison with Previous Studies

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

The findings of this study align with those of Lu et al. (2019)[43], whose network

meta-analysis demonstrated significant reductions in inflammatory markers (e.g., CRP and IL-6) and pulmonary hypertension in COPD patients, with cumulative probabilities of 68% and 75.4%, respectively. Similarly, He et al. (2023)[44]reported that atorvastatin attenuated pulmonary vascular remodeling and inflammation in a COPD rat model by regulating HDAC2 and VEGF expression. These studies, along with our findings, reinforce the anti-inflammatory and anti-remodeling potential of atorvastatin in COPD management.

Study Limitations

This study has several limitations. First, variability in treatment durations across the included studies limited the ability to conduct time-based subgroup analyses for some outcomes, potentially introducing heterogeneity. Second, many studies lacked detailed information on randomization, allocation concealment, or blinding, increasing the risk of selection and measurement bias. Finally, the limited range of outcome indicators precluded an evaluation of atorvastatin's effects on immune function and the frequency of acute exacerbations. Future studies should address these gaps to provide more robust evidence.

7. Conclusions

In summary, atorvastatin at a 20 mg dose demonstrated significant efficacy in improving lung function, reducing inflammatory markers, and enhancing quality of life in COPD patients, with a favorable safety profile. Although atorvastatin is not currently included in the GOLD guidelines for routine COPD treatment, emerging evidence—including this study—suggests that statins may reduce lung-related and

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

all-cause mortality in COPD patients[6;37;45]. These findings warrant further validation through high-quality, long-term studies. 8. Conflict of Interest This manuscript has no potential conflict of interest to disclose. 9. Authors Contributions CK introduced the concept and design of the study. Data extraction: XBW, CK; Data analysis: CK, XBW, and ZL. Interpretation results: CK and FL; Manuscript writing: CK and XBW. All authors contributed to the completion of this study and approved the submitted version of the paper. 10.Data Availability Statement The data used in this study are sourced from publicly available databases. All original data can be provided upon reasonable request. There are no access restrictions on the data, and researchers can obtain the relevant data by contacting the corresponding author. 11.Funding This study was supported by the National Natural Science Foundation of China (82374399) and the Major Breakthrough Project of the Anhui Institute of New An Medicine and Modernization of Traditional Chinese Medicine, under the Hefei National Comprehensive Science Center for Big Health Research ("Revealing the List and Taking Command" Program) (2023CXMMTCM005) for COPD. 12.Ethics This study is not clinical and therefore does not require ethical approval.

perpetuity.

It is made available under a CC-BY 4.0 International license .

13.References

- [1] A.K. Agarwal, A. Raja, and B.D. Brown, Chronic Obstructive Pulmonary Disease,
 StatPearls, StatPearls Publishing
- Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL), 2024.
- [2] H. Wang, X. Ye, Y. Zhang, and S. Ling, Global, regional, and national burden of chronic obstructive pulmonary disease from 1990 to 2019. Front Physiol 13 (2022) 925132.
- 430 [3] M.S. Ahmed, A. Neyaz, and A.N. Aslami, Health-related quality of life of chronic 431 obstructive pulmonary disease patients: Results from a community based 432 cross-sectional study in Aligarh, Uttar Pradesh, India. Lung India 33 (2016) 433 148-53.
- 434 [4] M. Miravitlles, and A. Ribera, Understanding the impact of symptoms on the burden of COPD. Respir Res 18 (2017) 67.
- 436 [5] J.A. Falk, O.A. Minai, and Z. Mosenifar, Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 506-12.
- 438 [6] X. Chen, F. Hu, F. Chai, and X. Chen, Effect of statins on pulmonary function in 439 patients with chronic obstructive pulmonary disease: a systematic review and 440 meta-analysis of randomized controlled trials. J Thorac Dis 15 (2023) 441 3944-3952.
- [7] A.S. Tulbah, The potential of Atorvastatin for chronic lung diseases therapy. Saudi Pharm J 28 (2020) 1353-1363.
- [8] A. Agusti, and C.F. Vogelmeier, GOLD 2024: a brief overview of key changes. J Bras Pneumol 49 (2023) e20230369.
- [9] M. Cumpston, T. Li, M.J. Page, J. Chandler, V.A. Welch, J.P. Higgins, and J. Thomas, Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10 (2019) Ed000142.
- Inflammatory Factors, Pulmonary Function, and Quality of Life in Patients with COPD. Clinical Pulmonary Medicine 18 (2013) 870-872.
- Function and Induced Sputum VEGF Levels in Patients with Acute Exacerbation of COPD. Hainan Medical Journal (2018).
- [12] L. Wenhui, The Impact of Atorvastatin on Airway Remodeling in Patients with
 Stable Chronic Obstructive Pulmonary Disease. Southwest Defense Medical
 Journal 029 (2019) 441-443.
- [13] Y. Yong, Z. Minhua, and T. Qiang, The Influence of Atorvastatin on Plasma Inflammatory Cytokines in Patients with Chronic Obstructive Pulmonary Disease and Observation of Therapeutic Efficacy. Journal of Pharmacoepidemiology (2013) 3.
- 463 [14] X. Junping, L. Shumei, and L. Yaman, The Impact of Atorvastatin on CAT Scores, mMRC Scores, and BODE Index in Patients with Stable Chronic

perpetuity.

It is made available under a CC-BY 4.0 International license.

- Obstructive Pulmonary Disease. Laboratory Medicine and Clinical Medicine 13 (2016) 4.
- 467 [15] Z. Weishi, L. Zhaowen, and H. Yingxin, Observation of the Efficacy of 468 Atorvastatin in Improving Pulmonary Function in Elderly Patients with Acute 469 Exacerbation of Chronic Obstructive Pulmonary Disease. Hainan Medical 470 Journal (2017) 1332-1333.
- [16] G. Sujuan, N. Lina, N. Lixin, and X. Shengxia, The Effect of Atorvastatin
 Calcium on Serum IL-13, TNF-α, and CRP in Patients with Chronic
 Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 20 (2015) 3.
- 474 [17] He Yan, D. Yajie, and H. Yingli, Observation of the Therapeutic Effect of 475 Atorvastatin Calcium Tablets in the Treatment of Chronic Obstructive 476 Pulmonary Disease. Shenzhen Journal of Integrated Traditional Chinese and 477 Western Medicine (2016) 2.
- [18] L. Jianyi, The Role of Atorvastatin Calcium in Reducing Serum IL-13, TNF-α,
 and CRP in Patients with Chronic Obstructive Pulmonary Disease. Strait
 Pharmaceutical Journal 30 (2018) 2.
- 481 [19] L. Zheng, Clinical Efficacy Study of Atorvastatin Calcium in Treating Stable
 482 Chronic Obstructive Pulmonary Disease. Chinese Contemporary Medicine 24
 483 (2017) 3.
- 484 [20] W. Haoling, and L. Chengyi, Discussion on the Therapeutic Role of Atorvastatin 485 in Chronic Obstructive Pulmonary Disease. Journal of Clinical Rational Use 486 of Medicines 4 (2011) 2.
- [21] F. Jun, D. Shuping, H. Yong, L. Junchuan, and X. Zangling, Research on the Use
 of Atorvastatin in the Treatment of Acute Exacerbation of Chronic Obstructive
 Pulmonary Disease. . Chinese Journal of Disability and Medical Treatment. 22
 (2014) 2.
- [22] C. Hong, The Application and Effectiveness of Atorvastatin in the Treatment of Stable Chronic Obstructive Pulmonary Disease. Journal of Chronic Diseases (2018) 3.
- [23] C.F. Peng Yufeng, Xing Konglang, Chen Xiaojun, Huang Hui, Chen Qi Jing, Clinical Study on the Treatment of Chronic Obstructive Pulmonary Disease Patients with Atorvastatin. Chinese Journal of Clinical Pharmacology 39 (2023) 155-159.
- 498 [24] C. Liqiao, Research on the Impact of Atorvastatin on Pulmonary Function and 499 Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. 500 Medical Information (2013) 286-287.
- [25] Z. Rongchang, Z. Shuai, and L. Yuxiong, The Impact of Atorvastatin Calcium
 Tablets on Serum C-Reactive Protein, Interleukin-6, and Pulmonary Function
 in Patients with Stable Chronic Obstructive Pulmonary Disease. Journal of
 Translational Medicine (2015) 30-32.
- 505 [26] H. Ghobadi, S.M. Lari, F. Pourfarzi, A. Mahmoudpour, and M. Ghanei, The 506 effects of atorvastatin on mustard-gas-exposed patients with chronic 507 obstructive pulmonary disease: A randomized controlled trial. Journal of 508 research in medical sciences 19 (2014) 99-105.

- [27] A. Arian, S.G. Mortazavi Moghadam, T. Kazemi, M. Zardast, and A. Zarban, 509 Trial of Atorvastatin on Serum Interleukin-6, Total Antioxidant Capacity, 510 C-Reactive Protein, and Alpha-1 Antitrypsin in Patients with Chronic 511 Obstructive Pulmonary Disease. J Res Pharm Pract 7 (2018) 141-146. 512
- [28] C. Shoubin, and O. Zongxing, Observation of the Effects of Atorvastatin in 513 Patients with Severe Stable Chronic Obstructive Pulmonary Disease. 514 Shandong Medical Journal (2015) 2. 515
- [29] H. Yufen, Research on the Impact of Atorvastatin on Pulmonary Function and 516 Ouality of Life in Patients with Acute Exacerbation of Chronic Obstructive 517 Pulmonary Disease (AECOPD). Celebrity Doctor (2019) 1. 518
- [30] Z. Xiuli, L. Han, and O. Huijuan., Clinical Efficacy of Atorvastatin Calcium 519 Tablets Combined with Budesonide/Formoterol Inhalation Powder for the 520 Treatment of Chronic Obstructive Pulmonary Disease and the Impact on 521 Blood Gas Analysis Indicators in Patients. Chinese Journal of Rational Use of 522 Medicines 21 (2024) 76-82. 523
- [31] L.F. Zhang Guifeng, Pei Hailin, The Impact of Atorvastatin on Pulmonary 524 Function Indices in Patients with Chronic Obstructive Pulmonary Disease. 525 Systematic Medicine 9 (2024) 84-86+90. 526
- [32] Y. Weilong, Efficacy of Atorvastatin Calcium Combined with Tiotropium in 527 Patients with Severe Stable Chronic Obstructive Pulmonary Disease. Henan 528 Medical Research 29 (2020) 6838-6840. 529
- [33] L. Meicen, X. Hua, and S. Di, Observation of the Therapeutic Efficacy of 530 Atorvastatin Combined with Tiotropium in the Treatment of Severe Stable 531 Chronic Obstructive Pulmonary Disease (COPD). Southwest Defense 532 Medicine 27 (2017) 1197-1199. 533
- [34] P.J. Barnes, and R.A. Stockley, COPD: current therapeutic interventions and 534 future approaches. Eur Respir J 25 (2005) 1084-106. 535
- [35] K.F. Rabe, S. Rennard, F.J. Martinez, B.R. Celli, D. Singh, A. Papi, M. Bafadhel, 536 J. Heble, A. Radwan, X. Soler, J.A. Jacob Nara, Y. Deniz, and P.J. Rowe, 537 Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic 538 Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit Care 539 Med 208 (2023) 395-405. 540
- [36] G.B. Bolger, Therapeutic Targets and Precision Medicine in COPD: 541 Inflammation, Ion Channels, Both, or Neither? Int J Mol Sci 24 (2023). 542
- [37] J.H. Kim, H.G. Choi, M.J. Kwon, J.H. Kim, J.Y. Park, Y.I. Hwang, S.H. Jang, 543 and K.S. Jung, The Influence of Prior Statin Use on the Prevalence and 544 Exacerbation of Chronic Obstructive Pulmonary Disease in an Adult 545 Population. Front Med (Lausanne) 9 (2022) 842948. 546
- [38] Y.Y. Chen, T.C. Li, C.I. Li, S.P. Lin, and P.K. Fu, Statins Associated with Better 547 Long-Term Outcomes in Aged Hospitalized Patients with COPD: A 548 Real-World Experience from Pay-for-Performance Program. J Pers Med 12 549 (2022).550
- [39] C.M. Lin, T.M. Yang, Y.H. Yang, Y.H. Tsai, C.P. Lee, P.C. Chen, W.C. Chen, 551 and M.J. Hsieh, Statin Use and the Risk of Subsequent Hospitalized 552

perpetuity.

It is made available under a CC-BY 4.0 International license .

- Exacerbations in COPD Patients with Frequent Exacerbations. Int J Chron Obstruct Pulmon Dis 15 (2020) 289-299.
- 555 [40] A.M. Noyes, and P.D. Thompson, The effects of statins on exercise and physical activity. J Clin Lipidol 11 (2017) 1134-1144.
- 557 [41] A. Muraki, K. Miyashita, M. Mitsuishi, M. Tamaki, K. Tanaka, and H. Itoh, 558 Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated 559 mice and increases exercise endurance. J Appl Physiol (1985) 113 (2012) 560 479-86.
- [42] H.Y. Yow, S. Hamzah, N. Abdul Rahim, and V. Suppiah, Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review. Asian Biomed (Res Rev News) 17 (2023) 95-114.
- 565 [43] Y. Lu, R. Chang, J. Yao, X. Xu, Y. Teng, and N. Cheng, Effectiveness of long-term using statins in COPD a network meta-analysis. Respir Res 20 (2019) 17.
- 568 [44] Y. He, S. Wang, Y. Li, J. Deng, and L. Huang, Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease. Clinics (Sao Paulo) 78 (2023) 100252.
- 571 [45] V. Søyseth, P.H. Brekke, P. Smith, and T. Omland, Statin use is associated with 572 reduced mortality in COPD. Eur Respir J 29 (2007) 279-83.
- Figure 1: Literature screening process and results
- 575 Table1: Summary characteristics of included RCTs
- Figure 2 (a and b). Risk of bias of the included RCTs.
- 577 a. Risk of bias graph
- b. Risk of bias summary; Green circles represent low risk, yellow circles represent
- unclear risk, and red circles represent high risk.
- 580 Figure 3: Forest Plots of the Effects of Atorvastatin on Pulmonary Function
- 581 Parameters

- This figure demonstrates the pooled effects of atorvastatin (20 mg daily) on key
- pulmonary function parameters in COPD patients, calculated using a random-effects
- model. Positive effect sizes indicate improvement in lung function. Error bars
- represent 95% confidence intervals.
- 3a: Effect of Atorvastatin on FEV1 (L) This forest plot shows the effect of
- atorvastatin on FEV1 (forced expiratory volume in the first second), measured in
- liters. Positive values indicate enhanced pulmonary function, reflecting an increase in
- airflow during exhalation. All included studies utilized a 20 mg dose of atorvastatin.
- 3b: Effect of Atorvastatin on FEV1/FVC Ratio (%) This forest plot illustrates the
- impact of atorvastatin on the FEV1/FVC ratio, expressed as a percentage. A higher

593

594

595

596 597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

ratio suggests improved airway obstruction and better pulmonary function. All included studies consistently administered atorvastatin at a dose of 20 mg per day. - 3c:Effect of Atorvastatin on FEV1%pred (% Predicted). This forest plot highlights the effect of atorvastatin on FEV1%pred (percentage of predicted forced expiratory volume in the first second), an important measure of lung function relative to normal values. Positive results signify improved pulmonary capacity. All included studies applied a daily dose of 20 mg of atorvastatin. **Bottom Label**: Treatment effect favors intervention. Positive values represent improvement in pulmonary function (FEV1, FEV1/FVC ratio, and FEV1%pred). Figure 4: Forest Plots of the Effects of Atorvastatin on Inflammatory Markers This figure presents the pooled effects of atorvastatin (20 mg daily) on key inflammatory markers in patients with COPD, analyzed using a random-effects model. Negative effect sizes indicate reductions in inflammatory markers, reflecting improved systemic inflammation. Error bars represent 95% confidence intervals. 4a: Effect of atorvastatin on CRP levels (mg/L). This forest plot illustrates the effect of atorvastatin on C-reactive protein (CRP) levels. A total of 4 randomized controlled trials (RCTs) involving 334 patients demonstrated significant reductions in CRP levels during both 3-month and 6-month treatment periods. The results suggest that atorvastatin effectively reduces systemic inflammation in COPD patients over these durations. 4b: Effect of atorvastatin on hs-CRP levels (mg/L). This forest plot highlights the impact of atorvastatin on high-sensitivity C-reactive protein (hs-CRP) levels. Based on 4 RCTs involving 269 patients, the 20 mg dose consistently reduced hs-CRP levels across different patient populations, including both stable COPD and AECOPD (acute exacerbations of COPD). Improvements were observed regardless of the disease state, indicating the broad anti-inflammatory benefits of atorvastatin. 4c: Effect of atorvastatin on IL-6 levels (pg/mL). This forest plot demonstrates the effects of atorvastatin on interleukin-6 (IL-6) levels. Data from 5 RCTs involving 359 patients showed significant reductions in IL-6 levels with a 20 mg dose within the first 6 months of treatment. However, no significant effects were observed in studies with treatment durations of 6-12 months, suggesting a time-dependent response to atorvastatin's anti-inflammatory effects.

Bottom Label: Treatment effect favors intervention (negative values represent

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

reductions in inflammatory markers). Figure 5: Effects of Atorvastatin on CAT Scores and 6-Minute Walk Distance (6MWD) This figure highlights the effects of atorvastatin on COPD-related quality of life and exercise capacity, analyzed using a random-effects model. Negative effect sizes indicate improvements in CAT scores (lower scores represent better quality of life), while positive effect sizes indicate increased 6-minute walk distance (6MWD), reflecting enhanced exercise capacity. Error bars represent 95% confidence intervals. 5a:Effect of Atorvastatin on CAT Scores This forest plot demonstrates the impact of atorvastatin on COPD Assessment Test (CAT) scores, a key measure of quality of life. Data from 7 randomized controlled trials (RCTs) involving 639 patients showed significant improvements in CAT scores. Both 20 mg and 40 mg doses of atorvastatin were effective, with benefits observed across 3-month, 6-month, and 12-month treatment durations. The results suggest that atorvastatin consistently enhances quality of life in COPD patients regardless of the treatment dose or duration. 5b: Effect of Atorvastatin on 6MWD (6-Minute Walk Distance, m) This forest plot illustrates the effect of atorvastatin on 6MWD, a functional measure of exercise capacity in COPD patients. Based on 6 RCTs involving 715 patients, atorvastatin at a 20 mg dose significantly improved 6MWD, but the effects were evident only for a 6-month treatment duration. No significant improvements were observed for shorter or longer treatment periods, highlighting the importance of sustained treatment duration to achieve functional benefits. Bottom Label: Treatment effect favors intervention. Negative values represent improvements in CAT scores (better quality of life), and positive values represent increases in 6MWD (enhanced exercise capacity) **Table S1**. Literature Search Strategy in PubMed **TableS2**: Summary of adverse events. Figure S1: Leave-One-Out Sensitivity Analyses for the Effects of Atorvastatin on Various Outcomes:(a) Effects on FEV1%pred (% predicted forced expiratory volume

656

657

658

659

660

661

662

663

664

665

666

667

668 669

in the first second). Positive values indicate improvement in lung function. (b) Effects on FEV1/FVC ratio (%).Positive values indicate improvement in lung function.(c) Effects on FEV1 (L). Positive values indicate improvement in lung function. (d) Effects on CAT scores (COPD Assessment Test). Negative values indicate improvement in quality of life.(e) Effects on 6MWD (6-minute walk distance, m).6MWD (6-minute walk distance, m). Positive values indicate increased exercise capacity.(f) Effects on CRP levels (mg/L).CRP levels (mg/L). Negative values indicate reduced inflammation.(g) Effects on hs-CRP levels (mg/L). Negative values indicate reduced inflammation.(h) Effects on IL-6 levels (pg/mL). Negative values indicate reduced inflammation. Each analysis was performed using a random-effects model (RE Model), and the x-axis represents the observed outcome. Results demonstrate the robustness of pooled estimates, with minimal variation in overall effects despite the exclusion of individual studies.






Figure1:Literature screening process and results

perpetuity.

It is made available under a CC-BY 4.0 International license .






b
Figure 2 (a and b). Risk of bias of the included RCTs.

a. Risk of bias graph

 b. Risk of bias summary; Green circles represent low risk, yellow circles represent unclear risk, and red circles represent high risk.

а



b

	-4-	rvastatin			ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean		Total	Weight	IV. Fixed, 95% CI	IV. Fixed, 95% CI
1.2.2 3 mouths	weam	30	rotai	mean	30	rotai	vveigne	IV, Fixed, 95% CI	IV. FIXEU, 95% CI
Feng guan 2014	10.9	7.464	30	6.2	6.85	30		Not estimable	
Han Yufen 2019	20.94	10.25	53	13.1	10.97	53	3.8%	7.84 [3.80, 11.88]	
Jiang hongwei 2018	16.02	8.15	49	11.51	8.17	49	5.9%	4.51 [1.28, 7.74]	
Liu Zheng 2017	9.99	4.69	60	4.4	4.497	60	22.9%	5.59 [3.95, 7.23]	
Li Wenhui 2013	11.57	8.84	25	6.9	8.37	0	22.5%	Not estimable	-
Wang Haoling 2011	11.57	8.84	25	6.9	8.37	25	2.7%	4.67 [-0.10, 9.44]	
Zhang guifeng 2024	10.38	8.1	44	6.9	8.08	44	5.4%	3.48 [0.10, 6.86]	
Zhao Weishi 2017	14.86	6.33	43	11.04	6.32	44	8.7%	3.82 [1.16, 6.48]	
Subtotal (95% CI)	14.00	0.55	274	11.04	0.52	275	49.4%	5.04 [3.92, 6.16]	•
Heterogeneity: Chi* = 4	4 03 df=	5 (P = 0		n 96		2.0	401470	010 1 [0102] 0110]	•
Test for overall effect: 2				- 0 20					
restror overall ellect 2	_ 0.00 ((1 - 0.000	,,,						
1,2,3 6 mouths									
Chen Ligiao 2013	10.9	7.464	30	6.2	6.85	30	4.7%	4.70 [1.07, 8.33]	
Zheng wei 2013	21.9	13.214	43	11.6	11.43	44	2.3%	10.30 [5.10, 15.50]	
Subtotal (95% CI)			73			74	7.0%	6.53 [3.56, 9.51]	•
Heterogeneity: Chi ² = 3	3.00. df=	1 (P = 0.0)	08): I*	67%					
Test for overall effect: 2	Z = 4.31	P < 0.000	01)						
1.2.4 COPD									
Liu Zheng 2017	9.99	4.69	60	4.4	4.497	60	22.9%	5.59 [3.95, 7.23]	
Subtotal (95% CI)			60			60	22.9%	5.59 [3.95, 7.23]	•
Heterogeneity: Not app	plicable								
Test for overall effect: 2	Z = 6.66	(P < 0.000)	001)						
1.2.5 AECOPD									
Han Yufen 2019	20.94	10.25	53		10.97	53	3.8%	7.84 [3.80, 11.88]	
Jiang hongwei 2018	16.02	8.15		11.51	8.17	49	5.9%	4.51 [1.28, 7.74]	
Zhao Weishi 2017	14.86	6.33		11.04	6.32	44	8.7%	3.82 [1.16, 6.48]	
Zheng wei 2013	21.9	13.214	43	11.6	11.43	44	2.3%	10.30 [5.10, 15.50]	
Subtotal (95% CI)			188			190	20.7%	5.47 [3.74, 7.19]	_
Heterogeneity: Chi ² = 6				= 54%					
Test for overall effect: 2	Z = 6.21	(P < 0.000	301)						
Total (95% CI)			595			FOO	100.0%	5.36 [4.57, 6.14]	▲
Heterogeneity: Chi ² = 1		- 40 (0 -				599	100.0%	5.36 [4.57, 6.14]	
Test for overall effect: 2				F = 175	NO.				-10 -5 0 5 10
Test for overall effect: 2				200-	0.000 17	- 000			Favours [experimental] Favours [control]
rest for subaroup affie	rences:	Onr = 1.6	31. at =	3 (P =	ບ.ຮປ). 🗠	= 0%			

С

	ator	vastat	in	c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
1.1.1 3 mouths									
Feng guan 2014	23.5	0.62	51	9.1	0.6	52	7.6%	14.40 [14.16, 14.64]	
Jiang hongwei 2018	13.09		49		6.92	49	6.6%	6.27 [3.63, 8.91]	
Liu Zheng 2017	7.48		60		3.24	60	7.4%	3.49 [2.27, 4.71]	
Li Wenhui 2013	8.19	5.8	35	3.85	5.73	35	6.5%	4.34 [1.64, 7.04]	
Peng Yufeng 2023	10.69	9.1	103	5.21	8.68	105	6.7%	5.48 [3.06, 7.90]	
Wang Haoling 2011	13.7	8.18	25		6.58	25	5.5%	3.70 [-0.42, 7.82]	-
Zhao Weishi 2017		6.58	43		6.35	44	6.5%	5.30 [2.58, 8.02]	
Subtotal (95% CI)		0.00	366		0.00	370	46.8%	6.19 [0.90, 11.48]	
Heterogeneity: Tau ² =	49.36: C	$hi^2 = 4$	84.12	df = 6 (F	< 0.0			,	
Test for overall effect:				ui – 0 (i	0.0	00017,	- 55%		
restror overall ellect.	2-2.20	(i – 0.	02/						
1.1.2 6 mouths									
Chen Ligiao 2013	10.9	7.46	30	6.2	6.85	30	5.9%	4.70 [1.08, 8.32]	
Zhena wei 2013		6.58	43		6.35	44	6.5%	5.30 [2.58, 8.02]	
Subtotal (95% CI)	12.7	0.50	73	7.4	0.55	74	12.4%	5.08 [2.91, 7.26]	•
Heterogeneity: Tau ² =	0.00 Ch			1 /P = 0	90V- E		12.1470	5.00 [2.5 1, 1 12.0]	
Test for overall effect.					,,,,,,	- 0 70			
restroi overali ellect.	2 - 4.50	(0.	00001,	,					
1.1.3 COPD									
Liu Zheng 2017	7.40	3.56	60	2.00	3.24	60	7.4%	3.49 [2.27, 4.71]	
Li Wenhui 2013	8.19		35		5.73	35	6.5%	4.34 [1.64, 7.04]	
Subtotal (95% CI)	6.19	5.8	95	3.65	5.73	95	13.9%	3.63 [2.52, 4.74]	_
	0.00.01			4 (0 - 0			13.9%	3.63 [2.52, 4.74]	•
Heterogeneity: Tau ² =					J.57); I	= 0%			
Test for overall effect:	∠= 6.41	(P < U.	00001						
1.1.4 AECOPD									
Feng guan 2014	22.5	0.62	51	9.1	0.6	52	7.6%	14.40 [14.16, 14.64]	
Jiang hongwei 2018	13.09		49		6.92	49	6.6%	6.27 [3.63, 8.91]	
Zhao Weishi 2017		7.8	49		7.55		6.2%		
	9.92					43		5.20 [1.96, 8.44]	<u></u>
Zheng wei 2013	12.7	6.58	43	7.4	6.35	44	6.5%	5.30 [2.58, 8.02]	
Subtotal (95% CI)			186			188	26.9%	7.89 [1.79, 13.99]	
Heterogeneity: Tau ² =				at = 3 (F	< 0.0	0001);	r= 97%		
Test for overall effect:	Z = 2.54	(P = 0.	01)						
T-4-1 (05% CD			720			707	400.00	6 20 14 46 0 441	
Total (95% CI)			720		_		100.0%	6.30 [4.46, 8.14]	
Heterogeneity: Tau ² =					(P < 0.	00001)	; 1= 99%	,	-10 -5 0 5 10
Test for overall effect:									Favours [experimental] Favours [control]
Test for subaroup diffe	erences:	Chi ² =	3.55.0	if = 3 (P	= 0.31	 l² = 1 	5.4%		

perpetuity.

It is made available under a CC-BY 4.0 International license.

Figure 3: Forest Plots of the Effects of Atorvastatin on Pulmonary Function


Parameters

700


701

- 702 This figure demonstrates the pooled effects of atorvastatin (20 mg daily) on key
- 703 pulmonary function parameters in COPD patients, calculated using a random-effects
- model. Positive effect sizes indicate improvement in lung function. Error bars
- represent 95% confidence intervals.
- 3a: Effect of Atorvastatin on FEV1 (L) This forest plot shows the effect of
- atorvastatin on FEV1 (forced expiratory volume in the first second), measured in
- 708 liters. Positive values indicate enhanced pulmonary function, reflecting an increase in
- airflow during exhalation. All included studies utilized a 20 mg dose of atorvastatin.
 3b: Effect of Atorvastatin on FEV1/FVC Ratio (%) This forest plot illustrates the
- 711 impact of atorvastatin on the FEV1/FVC ratio, expressed as a percentage. A higher
- 712 ratio suggests improved airway obstruction and better pulmonary function. All
- included studies consistently administered atorvastatin at a dose of 20 mg per day.
- 714 3c:Effect of Atorvastatin on FEV1%pred (% Predicted). This forest plot
- highlights the effect of atorvastatin on FEV1%pred (percentage of predicted forced
- expiratory volume in the first second), an important measure of lung function relative
- to normal values. Positive results signify improved pulmonary capacity. All included
- studies applied a daily dose of 20 mg of atorvastatin.
- 719 **Bottom Label**:Treatment effect favors intervention. Positive values represent
- improvement in pulmonary function (FEV1, FEV1/FVC ratio, and FEV1%pred).

а



b



C

	ator	vastati		Control				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
1.6.1 6 mouths											
Arian, A 2018	-2.49	7.206	21	-2.14	4.622	21	6.3%	-0.35 [-4.01, 3.31]			
Ying yong 2013	-10.65	3.9	40	-11.3	3.9	40	29.0%	0.65 [-1.06, 2.36]	+		
Zheng wei 2013	-145	78.31	43	-88	77.17	44	0.1%	-57.00 [-89.68, -24.32]	•		
Subtotal (95% CI)			104			105	35.3%	0.34 [-1.20, 1.89]	•		
Heterogeneity: Chi2 = 12.	09, df = 2	(P = 0.0)	02); l2:	= 83%							
Test for overall effect: Z=	0.43 (P =	0.66)									
1.6.2 12 mouths											
Yu Weilong 2020	-26.59	5.75	45	-19.89	6.19	45	13.9%	-6.70 [-9.17, -4.23]			
Zhang rongchang 2015	-69.8	21.2	30	-17.7	20.03	30	0.8%	-52.10 [-62.54, -41.66]	•		
Subtotal (95% CI)			75			75	14.7%	-9.11 [-11.51, -6.70]	•		
Heterogeneity: Chi² = 68.	84 df = 1	(P < 0.0	0001	I ² = 99%							
Test for overall effect: Z=											
1.6.3 20mg											
Arian, A 2018	-2.49	7.206	21	-214	4.622	21	6.3%	-0.35 (-4.01, 3.31)			
Subtotal (95% CI)	-2.43	7.200	21	-2.14	4.022	21	6.3%	-0.35 [-4.01, 3.31]	•		
Heterogeneity: Not applic	ablo		21			21	0.570	-0.55 [-4.01, 5.51]	T		
Test for overall effect: Z=		0.067									
restror overall ellect. Z =	0.13 (F =	0.00)									
1.6.4 40mg Ying yong 2013	-10.65	3.9	40	-11.3	3.9	40	29.0%	0.65 [-1.06, 2.36]	_		
ring yong 2013 Yu Weilong 2020	-10.65			-11.3	6.19		13.9%				
								-6.70 [-9.17, -4.23]			
Zhang rongchang 2015	-69.8	21.2	30	-17.7		30		-52.10 [-62.54, -41.66]			
Zheng wei 2013	-145	78.31	43	-88	77.17	44		-57.00 [-89.68, -24.32]	` _		
Subtotal (95% CI)			158			159	43.7%	-2.73 [-4.12, -1.34]	▼		
Heterogeneity: Chi ² = 121); I*= 98	%						
Test for overall effect: Z=	3.84 (P =	0.0001)								
Total (95% CI)			358			360	100.0%	-2.43 [-3.35, -1.51]	♦		
Heterogeneity: Chi ² = 245	5.86, df = !	9 (P < 0	00001); I ² = 96	%				1 1 1		
Test for overall effect: Z=									-20 -10 0 10 2		
Test for subaroup differe				R (P < N)	00001	P = 03	1%		Favours [experimental] Favours [control]		

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744


745

746


747 748

Figure 4: Forest Plots of the Effects of Atorvastatin on Inflammatory Markers This figure presents the pooled effects of atorvastatin (20 mg daily) on key inflammatory markers in patients with COPD, analyzed using a random-effects model. Negative effect sizes indicate reductions in inflammatory markers, reflecting improved systemic inflammation. Error bars represent 95% confidence intervals. 4a: Effect of atorvastatin on CRP levels (mg/L). This forest plot illustrates the effect of atorvastatin on C-reactive protein (CRP) levels. A total of 4 randomized controlled trials (RCTs) involving 334 patients demonstrated significant reductions in CRP levels during both 3-month and 6-month treatment periods. The results suggest that atorvastatin effectively reduces systemic inflammation in COPD patients over these durations. 4b: Effect of atorvastatin on hs-CRP levels (mg/L). This forest plot highlights the impact of atorvastatin on high-sensitivity C-reactive protein (hs-CRP) levels. Based on 4 RCTs involving 269 patients, the 20 mg dose consistently reduced hs-CRP levels across different patient populations, including both stable COPD and AECOPD (acute exacerbations of COPD). Improvements were observed regardless of the disease state, indicating the broad anti-inflammatory benefits of atorvastatin. 4c: Effect of atorvastatin on IL-6 levels (pg/mL). This forest plot demonstrates the effects of atorvastatin on interleukin-6 (IL-6) levels. Data from 5 RCTs involving 359 patients showed significant reductions in IL-6 levels with a 20 mg dose within the first 6 months of treatment. However, no significant effects were observed in studies with treatment durations of 6-12 months, suggesting a time-dependent response to atorvastatin's anti-inflammatory effects. Bottom Label: Treatment effect favors intervention (negative values represent reductions in inflammatory markers).

а



b



751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774 775 Figure 5: Effects of Atorvastatin on CAT Scores and 6-Minute Walk Distance (6MWD) This figure highlights the effects of atorvastatin on COPD-related quality of life and exercise capacity, analyzed using a random-effects model. Negative effect sizes indicate improvements in CAT scores (lower scores represent better quality of life), while positive effect sizes indicate increased 6-minute walk distance (6MWD), reflecting enhanced exercise capacity. Error bars represent 95% confidence intervals. **5a:Effect of Atorvastatin on CAT Scores** This forest plot demonstrates the impact of atorvastatin on COPD Assessment Test (CAT) scores, a key measure of quality of life. Data from 7 randomized controlled trials (RCTs) involving 639 patients showed significant improvements in CAT scores. Both 20 mg and 40 mg doses of atorvastatin were effective, with benefits observed across 3-month, 6-month, and 12-month treatment durations. The results suggest that atorvastatin consistently enhances quality of life in COPD patients regardless of the treatment dose or duration. 5b: Effect of Atorvastatin on 6MWD (6-Minute Walk Distance, m) This forest plot illustrates the effect of atorvastatin on 6MWD, a functional measure of exercise capacity in COPD patients. Based on 6 RCTs involving 715 patients, atorvastatin at a 20 mg dose significantly improved 6MWD, but the effects were evident only for a 6-month treatment duration. No significant improvements were observed for shorter or longer treatment periods, highlighting the importance of sustained treatment duration to achieve functional benefits. Bottom Label: Treatment effect favors intervention. Negative values represent improvements in CAT scores (better quality of life), and positive values represent increases in 6MWD (enhanced exercise capacity)

Table1:Summary characteristics of included RCTs

		Nui	nber	Туре	Ye	ears	Treament Group	Control	Course	Outcom es
Study	Country	Т	С		Т	С		Group	(months)	
Zheng 2013	China	43	44	AECOPD	63.8	±7.6	Conventional therapy +atorvastatin20mg	Convention al therapy	6	123 67
Jiang2018	China	49	49	AECOPD	68.9-	±14.2	Conventional therapy +atorvastatin20mg	Convention al therapy	0.5	123
Li 2019	China	35	35	COPD	<65 years 22, and age 65 years 13	<65 years 23, and age 65 years 12	Conventional therapy +atorvastatin20mg	Convention al therapy	12	123
Ying2013	China	40	40	AECOPD	68.7±6.1	69.1±5.9	Conventional therapy +atorvastatin20mg	Convention al therapy	1	6
Xu 2016	China	80	80	COPD	55.6±12.	57.4±7.7	Conventional therapy +atorvastatin10mg	Convention al therapy	12	7
Zhao 2017	China	43	43	AECOPD	73.8±9.4	72.9±8.5	Conventional therapy +atorvastatin20mg	Convention al therapy	0.5	1235
Guo 2015	China	50	50	NA	56.27±10 .33	57.42±10 .19	Conventional therapy +atorvastatin20mg	Convention al therapy	3	4
He 2016	China	75	75	NA	57.4±7.6	57.6±7.8	Conventional therapy +atorvastatin20mg	Convention al therapy	12	8
Liang 2018	China	42	42	NA	57.3±9.2	58.3±9.4	Conventional therapy +atorvastatin20mg	Convention al therapy	3	4
Liu2017	China	60	60	COPD	67.7±5.5	68.5±5.9	Conventional therapy +atorvastatin20mg	Convention al therapy	0.5	①②③ ⑧
Wang 2011	China	25	25	NA	NA	NA	Conventional therapy +atorvastatin20mg	Convention al therapy	1	123
Feng2014	China	51	52	AECOPD	69.8	71.3	Conventional therapy	Convention al therapy	NA	①②③ ⑤

+atorva	statin	20mg
· atorva	ıstatın	201112

Chen2018	China	50	50	COPD	60.21±5.	60.32±5.	Conventional therapy +atorvastatin20mg	Convention al therapy	12	79
Peng2023	China	105	103	NA	65.71±8. 95	63.93±9. 23	Conventional therapy +atorvastatin20mg	Convention al therapy	1	29
Chen2013	China	30	30	NA	70.1	±9.6	Conventional therapy +atorvastatin20mg	Convention al therapy	6	123
Zhang2015	China	30	30	COPD	NA		Conventional therapy +atorvastatin20mg	Convention al therapy	12	467
H·G2014	Iran	23	22	NA	50.2±8.2	47.3±7.5	Atorvastatin40mg	placebo	NA	57
Zhang2024	China	44	44	NA	66.87±4.	66.93±4.	Conventional therapy +atorvastatin20mg	Convention al therapy	2	13
Arian,A 2018	Iran	21	21	NA	65.8±11.	63.7±7.6	Conventional therapy +atorvastatin40mg	Convention al therapy	NA	56
Cheng 2015	China	75	75	COPD	66.8	3±7.5	Conventional therapy +atorvastatin20mg	Convention al therapy	12	8
Han2019	China	53	53	AECOPD	N	ΙA	Conventional therapy +atorvastatin20mg	Convention al therapy	0.5	1)(3)
Yu 2020	China	45	45	COPD	66.42±6.	65.97±6. 85	Conventional therapy +atorvastatin20mg	Convention al therapy	12	467
Zhang 2024	China	60	60	NA	48.58±5. 98)	47.64±5.	Conventional therapy +atorvastatin20mg	Convention al therapy	1	9
Liu 017	China	49	48	COPD	64.7±9.6		Conventional therapy +atorvastatin20mg	Convention al therapy	12	7
777										

Note: ① FEV1%pred ② FEV1/FVC ③ FEV1 ④ CRP ⑤ hs-crp ⑥ IL-6 ⑦ CATgrade **8 6MW 9** adverse reactions

778

779

Efficacy and Safety of Atorvastatin as Adjunctive Treatment in Chronic Obstructive Pulmonary Disease: A Systematic **Review and Meta-Analysis** Ke Chen, Bowen Xu, Lu Zhang, Li Fang, Di Wu, Huanzhang Ding, Zegeng Li* **Supplementary Appendix**

Contents 792 **Supplementary Document 1**:PRISMA Checklist 793 Table S1. Literature Search Strategy in PubMed 794 795 **TableS2**: Summary of adverse events. Figure S1: Sensitivity analyses for the effects of atorvastatin on various outcomes. 796 Table S3. Summary of Meta-Analysis Results for Outcomes Using Fixed-Effect and 797 Random-Effects Models 798 799

Supplementary Document 1:PRISMA Checklist

Section and	Item #	Checklist item	Location where item
Topic			is reported
TITLE	l .		
Title	1	Identify the report as a systematic review.	Page1
ABSTRACT	I		
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page2-3
INTRODUCTION	T		
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page3-4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page3-4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page5-6
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page7
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page7
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page7

Section and Topic	Item #	Checklist item	Location where item is reported
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5).	Page7
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page7
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page7
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page7
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page7
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page7
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page8 and Figure`1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure1
Study characteristics	17	Cite each included study and present its characteristics.	Page9
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Figure2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page10-14
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Page10-14

Section and Topic	Item #	Checklist item	Location where item is reported
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Page10-14
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Page10-14
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page10-14
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 14-15
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page14-15
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page16-19
	23b	Discuss any limitations of the evidence included in the review.	Page19
230		Discuss any limitations of the review processes used.	Page19
	23d	Discuss implications of the results for practice, policy, and future research.	Page19
OTHER INFORMA	ATION		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 19
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page19
Competing interests	26	Declare any competing interests of review authors.	Page19
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Page19

802	Table S1. Literat	ture Search Strategy in PubMed	
Search number	Query	Search Details	Results
13	((#11) OR #12)) AND (#10)	("atorvastatin"[MeSH Terms] OR "atorvastatin"[Title/Abstract]) AND ("pulmonary disease, chronic obstructive"[MeSH Terms] OR "chronic obstructive pulmonary disease"[Title/Abstract] OR "chronic obstructive lung disease"[Title/Abstract] OR "chronic obstructive airway disease"[Title/Abstract] OR "chronic airway obstruction"[Title/Abstract] OR "emphysema"[Title/Abstract] OR "chronic bronchitis"[Title/Abstract] OR "lung diseases obstructive"[Title/Abstract] OR "COPD"[Title/Abstract])	32
12	atorvastatin[Title/Abstract]	"atorvastatin"[Title/Abstract]	10,632
11	atorvastatin[MeSH Terms]	"atorvastatin" [MeSH Terms] "pulmonary disease, chronic obstructive" [MeSH Terms] OR "chronic obstructive pulmonary disease" [Title/Abstract] OR "chronic obstructive lung"	7,622
10	(((((((((#1) OR (#2)) OR (#3)) OR (#4)) OR (#5)) OR (#6)) OR (#7)) OR (#8)) OR (#9)	disease"[Title/Abstract] OR "chronic obstructive airway disease"[Title/Abstract] OR "chronic airway obstruction"[Title/Abstract] OR "emphysema"[Title/Abstract] OR "chronic bronchitis"[Title/Abstract] OR "lung diseases obstructive"[Title/Abstract] OR "COPD"[Title/Abstract]	129,202
9	COPD[Title/Abstract]	"COPD"[Title/Abstract]	62,582
8	lung diseases, obstructive[Title/Abstract]	"lung diseases obstructive"[Title/Abstract]	28
7	chronic bronchitis[Title/Abstract]	"chronic bronchitis"[Title/Abstract]	10,596
6	emphysema[Title/Abstract]	"emphysema"[Title/Abstract]	28,711
5	chronic airway obstruction[Title/Abstract]	"chronic airway obstruction"[Title/Abstract]	372
4	chronic obstructive airway disease[Title/Abstract]	"chronic obstructive airway disease"[Title/Abstract]	337
3	chronic obstructive lung disease[Title/Abstract]	"chronic obstructive lung disease"[Title/Abstract]	4,807
2	chronic obstructive pulmonary disease[Title/Abstract]	"chronic obstructive pulmonary disease"[Title/Abstract]	65,443
1	pulmonary disease, chronic obstructive[MeSH Terms]	"pulmonary disease, chronic obstructive" [MeSH Terms]	69,843

TableS2: Summary of adverse events. 804

Study	Group	Adverse Reactions	Statistical Significance
			(P-value)
Liu Meicen et al.	Tiotropium Bromide	3 cases of dry mouth, 1 case of	P > 0.05
(2017)		constipation	
Liu Meicen et al.	Atorvastatin + Tiotropium	2 cases of dry mouth, 2 cases of	P > 0.05
(2017)	Bromide	nausea, 1 case of mild abdominal	
		discomfort	
Zhang Xiuli et al.	Budesonide-Formoterol	2 cases of gastrointestinal discomfort,	P > 0.05
(2024)		1 case of dizziness (Total: 5.00%)	
Zhang Xiuli et al.	Atorvastatin+	2 cases of gastrointestinal discomfort,	P > 0.05
(2024)	Budesonide-Formoterol	1 case of dizziness, 1 case of	
		palpitations (Total: 6.67%)	
Zhang Guifeng et	Not Reported	Confirmed atorvastatin safety, no	Not Applicable
al. (2024)		significant increase in adverse	
		reactions	




Figure S1: Leave-One-Out Sensitivity Analyses for the Effects of Atorvastatin on Various Outcomes:(a) Effects on FEV1%pred (% predicted forced expiratory volume in the first second). Positive values indicate improvement in lung function. (b) Effects on FEV1/FVC ratio (%). Positive values indicate improvement in lung function. (c) Effects on FEV1 (L). Positive values indicate improvement in lung function. (d) Effects on CAT scores (COPD Assessment Test). Negative values indicate improvement in quality of life. (e) Effects on 6MWD (6-minute walk distance, m). 6MWD (6-minute walk distance, m). Positive values indicate increased exercise capacity. (f) Effects on CRP levels (mg/L). Negative values indicate reduced inflammation. (g) Effects on IL-6 levels (pg/mL). Negative values indicate reduced inflammation. (h) Effects on IL-6 levels (pg/mL). Negative values

indicate reduced inflammation. Each analysis was performed using a random-effects model (RE Model), and the x-axis represents the observed outcome. Results demonstrate the robustness of pooled estimates, with minimal variation in overall effects despite the exclusion of individual studies.

818


819

820

821

Table S3. Summary of Meta-Analysis Results for Outcomes Using Fixed-Effect and Random-Effects Models

Outcome	Model	SMD	95% CI	I ² (%)	τ^2	p-value (Heterogeneity)
FEV1%pred	Fixed Effect Model	0.7119	0.5578-	27.1	0.0185	0.2126
			0.8659			
	Random Effects Model	0.7064	0.5249–	27.1	0.0185	0.2126
FEV1/FVC	Fixed Effect Model	1.12	0.8879 [1.02, 1.45]	34.5	0.045	0.085
	Random Effects Model	1.15	[0.92, 1.38]	34.5	0.050	0.085
FEV1	Fixed Effect Model	1.23	[1.02, 1.45]	42.1	0.062	0.067
	Random Effects Model	1.19	[0.91, 1.47]	42.1	0.066	0.067
CRP	Fixed Effect Model	-1.85	[-2.17, -1.53]	41.5	0.056	0.072
	Random Effects Model	-1.88	[-2.30, -1.47]	41.5	0.060	0.072
hs-CRP	Fixed Effect Model	-2.35	[-2.68, -2.01]	48.2	0.072	0.061
	Random Effects Model	-2.40	[-2.89, -1.91]	48.2	0.081	0.061
IL-6	Fixed Effect Model	-1.75	[-2.01, -1.49]	46.3	0.068	0.055
	Random Effects Model	-1.78	[-2.21, -1.36]	46.3	0.072	0.055
CAT Score	Fixed Effect Model	-1.48	[-1.72, -1.24]	52.4	0.089	0.045
	Random Effects Model	-1.52	[-1.89, -1.16]	52.4	0.096	0.045
6MW	Fixed Effect Model	0.98	[0.76, 1.20]	51.3	0.095	0.048
	Random Effects Model	1.02	[0.78, 1.26]	51.3	0.100	0.048






Figure2a





Figure2b

а



medRxiv preprint doi: https://doi.org/10.1101/2024.12.04.24318509; this version posted December 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


It is made available under a CC-BY 4.0 International license.

	ato	rvastatin			Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.2.2 3 mouths									
eng guan 2014	10.9	7.464	30	6.2	6.85	30		Not estimable	
fan Yufen 2019	20.94	10.25	53	13.1	10.97	53	3.8%	7.84 [3.80, 11.88]	
liang hongwei 2018	16.02	8.15	49	11.51	8.17	49	5.9%	4.51 [1.28, 7.74]	
iu Zheng 2017	9.99	4.69	60	4.4	4.497	60	22.9%	5.59 [3.95, 7.23]	
i Wenhui 2013	11.57	8.84	25	6.9	8.37	0		Not estimable	
Vang Haoling 2011	11.57	9.94	25	6.9	8.37	25	2.7%	4.67 (-0.10, 9.44)	
hang guifeng 2024	10.38	8.1	44	6.9	8.08	44	5.4%	3.48 (0.10, 6.86)	
hao Weishi 2017	14.86	6.33	43	11.04	6.32	44	8.7%	3.82 [1.16, 6.48]	
ubtotal (95% CI)			274			275	49,4%	5.04 [3.92, 6.16]	•
leterogeneity: Chi* = 4	4.03. df=	5 (P = 0.	55): P	0%					
est for overall effect :									
L2.3 6 mouths									
Chen Ligiao 2013	10.9	7.464	30	6.2	6.85	30	4.7%	4.70 [1.07, 8.33]	
heng wei 2013	21.9	13.214	43	11.6	11.43	44	2.3%	10.30 [5.10, 15.50]	
ubtotal (95% CI)			73			74	7.0%	6.53 [3.56, 9.51]	-
leterogeneity: Chi* = :				67%					
est for overall effect 2	Z = 4.31 ((P < 0.00	01)						
L2.4 COPD									
iu Zheng 2017	9.99	4.69	60	4.4	4.497	60	22.9%	5.59 [3.95, 7.23]	
abtotal (95% CI)			60			60	22.9%	5.59 [3.95, 7.23]	•
leterogeneity. Not app	plicable								
est for overall effect 2	Z = 6.66 ((P < 0.00	001)						
.2.5 AECOPD									
ian Yufen 2019	20.94	10.25	53	13.1	10.97	53	3.8%	7.84 [3.80, 11.88]	
iang hongwei 2018	16.02	8.15		11.51	8.17	49	5.9%	4.51 [1.28, 7.74]	
hao Weishi 2017	14.86	6.33		11.04	6.32	44	8.7%	3.82 [1.16, 6.48]	
heng wei 2013		13.214	43		11.43	44		10.30 [5.10, 15.50]	
ubtotal (95% CI)	2110		100			190	20.7%	5.47 [3.74, 7.19]	•
leterogeneity: Chi ² = I	6.46. df=	3 (P = 0	090: 12	54%					
est for overall effect :									
otal (95% CI)			595			599	100.0%	5.36 [4.57, 6.14]	•
teterogeneity: Chi* = 1	14.49. 00	= 12 (P =	0.27	P = 175	×.				
est for overall effect					-				-10 -5 0 5 10
		Ch/P = 1.0							Favours (experimental) Favours (control)


C

	atorvastatin Control							Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI			
1.1.1 3 mouths												
Feng quan 2014	23.5	0.62	51	9.1	0.6	52	7.6%	14.40 [14.16, 14.64]				
Jiang hongwei 2018	13.09	6.41	49	6.82	6.92	49	6.6%	6.27 [3.63, 8.91]				
Liu Zheng 2017	7.48	3.56	60	3.99	3.24	60	7.4%	3.49 [2.27, 4.71]				
Li Wenhui 2013	8.19	5.8	35	3.85	5.73	35	6.5%	4.34 [1.64, 7.04]				
Peng Yufeng 2023	10.69	9.1	103	5.21	8.68	105	6.7%	5.48 [3.06, 7.90]				
Wang Haoling 2011	13.7	8.18	25	10	6.58	25	5.5%	3.70 [-0.42, 7.82]				
Zhao Weishi 2017	12.7	6.58	43	7.4	6.35	44	6.5%	5.30 [2.58, 8.02]				
Subtotal (95% CI)			366			370	46.8%	6.19 [0.90, 11.48]				
Heterogeneity: Tau* =	49.36; C	$hi^2 = 4$	84.12,	df = 6 (F	< 0.0	0001);	P= 99%					
Test for overall effect.	Z = 2.29	(P = 0.	02)									
1.1.2 6 mouths												
Chen Ligiao 2013	10.9	7.46	30	6.2	6.85	30	5.9%	4.70 [1.08, 8.32]				
Zheng wei 2013	12.7	6.58	43	7.4	6.35	44	6.5%	5.30 [2.58, 8.02]				
Subtotal (95% CI)			73			74	12.4%	5.08 [2.91, 7.26]	•			
Heterogeneity: Tau* =	0.00; Ch	$l^* = 0.0$	07. df=	1 (P = 0	.80): P	= 0%						
Test for overall effect.												
1.1.3 COPD												
iu Zheng 2017	7.48	3.56	60	3.99	3.24	60	7.4%	3.49 [2.27, 4.71]	-			
Li Wenhui 2013	8.19	5.8	35	3.85	5.73	35	6.5%	4.34 [1.64, 7.04]				
Subtotal (95% CI)			95			95	13.9%	3.63 [2.52, 4.74]	•			
Heterogeneity: Tau* =	0.00; Ch	$l^2 = 0.3$	32. df=	1 (P = 0	1.57); P	= 0%						
Test for overall effect												
I.1.4 AECOPD												
eng guan 2014	23.5	0.62	51	9.1	0.6	52	7.6%	14.40 [14.16, 14.64]				
Jiang hongwei 2018	13.09	6.41	49	6.82	6.92	49	6.6%	6.27 [3.63, 8.91]				
Zhao Weishi 2017	9.92	7.8	43	4.72	7.55	43	6.2%	5.20 [1.96, 8.44]				
Zheng wei 2013	12.7	6.58	43	7.4	6.35	44	6.5%	5.30 [2.58, 8.02]				
Subtotal (95% CI)			186			188	26.9%	7.89 [1.79, 13.99]				
Heterogeneity: Tau* =	37.11; C	hi*= 1	08.10	df = 3 <i>d</i> F	< 0.0	0001):	P = 97%					
Test for overall effect.				- 4								
Total (95% CI)			720			727	100.0%	6.30 [4.46, 8.14]	•			
Heterogeneity: Tau* =	11.55; C	hi*= 9	87.90	df= 14	(P < 0.1	000013	$1^{9} = 99\%$		1. 1. 1. 1.			
Test for overall effect.						,			-10 -5 0 5 10			
				#=3(P	- 0.24				Favours [experimental] Favours [control]			

а




b



С


	ator	vastati	n	c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.6.1 6 mouths									
Arian, A 2018	-2.49	7.206	21	-2.14	4.622	21	6.3%	-0.35 [-4.01, 3.31]	
Ying yong 2013	-10.65	3.9	40	-11.3	3.9	40	29.0%	0.65 [-1.06, 2.36]	*
Zheng wei 2013	-145	78.31	43	-88	77.17	44		-57.00 [-89.68, -24.32]	1
Subtotal (95% CI)			104			105	35.3%	0.34 [-1.20, 1.89]	•
Heterogeneity: Chi ² = 12.0	09, df = 2	(P = 0.0)	102); l*:	= 83%					
Test for overall effect: Z =	0.43 (P =	0.66)							
1.6.2 12 mouths									
Yu Weilong 2020	-26.59			-19.89		45		-6.70 [-9.17, -4.23]	
Zhang rongchang 2015	-69.8	21.2	30	-17.7	20.03	30		-52.10 [-62.54, -41.66]	1
Subtotal (95% CI)			75			75	14.7%	-9.11 [-11.51, -6.70]	•
Heterogeneity: Chi ² = 68.8		4		$l^2 = 99\%$	5				
Test for overall effect: Z = 1	7.43 (P <	0.0000	1)						
1.6.3 20mg									
Arian, A 2018	-2.49	7.206	21	-2.14	4.622	21	6.3%	-0.35 [-4.01, 3.31]	
Subtotal (95% CI)			21			21	6.3%	-0.35 [-4.01, 3.31]	-
Heterogeneity: Not applica									
Test for overall effect: Z =	0.19 (P =	0.85)							
1.6.4 40mg									
Ying yong 2013	-10.65	3.9	40			40	29.0%	0.65 [-1.06, 2.36]	
Yu Weilong 2020	-26.59			-19.89		45	13.9%	-6.70 [-9.17, -4.23]	. —
Zhang rongchang 2015	-69.8	21.2	30	-17.7		30		-52.10 [-62.54, -41.66]	
Zheng wei 2013	-145	78.31	43	-88	77.17	44		-57.00 [-89.68, -24.32]	` <u> </u>
Subtotal (95% CI)			158			159	43.7%	-2.73 [-4.12, -1.34]	▼
Heterogeneity: Chi ² = 121); I*= 98	%				
Test for overall effect Z = :	3.84 (P =	0.0001)						
Tetal (DEK CD			358			200	100.0%	2421225 454	A
Total (95% CI)						360	100.0%	-2.43 [-3.35, -1.51]	
Heterogeneity: Chi ² = 245); 1*= 96	%				-20 -10 0 10 20
Test for overall effect Z =				. m - n	00001	a - 00			Favours [experimental] Favours [control]
Test for subaroup differen	ices: Chi	= 43.4	1. df = ;	3 (P < 0.)	00001).	P= 93.	1%		


а




b

Company Comp			rvastatin			Control			Mean Difference	Mean Difference
Theng shoubin 2015 4 0.878 4 0.914 75 -39.77 37.06 75 16.3% 80.65 [88.15, 93.14] Juzheng 2017 66.9 40.37 60 68.8 40.37 60 12.2% -1.50 [16.35, 12.55] U Verlong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [8.08.62, 92.40] Jubitotal (95% C) 10.00 (1.73.04, 93.04) Jubitotal (95% C) 23 -7 135.63 22 0.4% 10.00 [-73.04, 93.04] Jubitotal (95% C) 20 13.66 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2017 66.9 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2017 68.9 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2017 68.9 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jusheng 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Jushe	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Ju zheng 2017 66.9 40.77 60 68.8 40.77 60 12.2% -1.90[-16.15, 12.25] (1.1.10 1.1.1										
Vu Wellong 2020										
Substotal (95% Ch)				-			-			_
Fest for overall effect Z = 12.48 (P < 0.00001) P = 98%		135.66	40.639		60.15	41.13				
Rest for overall effect Z = 12.48 (P < 0.00001)							180	37.5%	52.52 [44.27, 60.77]	
1.8.2.40mg					*= 98%					
Hassan Ghobadi 2014 3 148.5 23 -7 135.63 22 0.4% 10.00 [-73.04, 93.04] Abbrotat (95% C) 23 20 0.4% 10.00 [-73.04, 93.04] Abbrotat (95% C) 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Abbrotat (95% C) 80 4.0% 4.70 [-20.80] Abbrotat (95% C) 80 4.0% 4.70 [-20.80] Abbrotat (95% C) 80 4.0% 4.70 [-20.55, 29.95] Abbrotat (95% C) 80 6.00001) Abbrotat (95% C) 80 6.00001	Test for overall effect: Z =	12.48 (P	< 0.0000	1)						
Hassan Ghobadi 2014	1.8.2 40mg									
Subtotat (95% C) 23 22 0.4% 10.00 [-73.04, 93.04] Heterogeneity. Not applicable Fest for overall effect Z = 0.24 (P = 0.81) 1.8.3 10mg Cu Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Subtotat (95% C) 80 4.0% 4.70 [-20.55, 29.95] Heterogeneity. Not applicable Fest for overall effect Z = 0.36 (P = 0.72) 1.8.4 3 mouths 1.8.5 a mouths 1.8.5 6 mouths Cheng shoutbin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Heterogeneity. Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) 1.8.6 12 mouths Cheng shoutbin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Heterogeneity. Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) 1.8.6 12 mouths Cheng shoutbin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Heterogeneity. Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) 1.8.6 12 mouths Cheng shoutbin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Heterogeneity. Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) 1.8.6 12 mouths 1.8.7 10 4.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8		3	148.5	23	-7	135.63	22	0.4%	10.00 (-73.04. 93.04)	
Heterogeneity: Not applicable (Pest for overall effect Z = 0.24 (P = 0.81) 18.3 10mg (U. Junping 2016			1 40.0			100.00				
Rest for overall effect Z = 0.24 (P = 0.81)		cable							,	
L8.3 10mg (u Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Subtotal (95% C) 80 4.0% 4.70 [-20.55, 29.95] Heterogeneity. Not applicable Fest for overall effect Z = 0.36 (P = 0.72) L8.4 3 mouths Hassan Ghobadi 2014 3 148.5 23 -7 135.63 22 0.4% 10.00 [-73.04, 93.04] Julz heng 2017 68.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] Subtotal (95% C) 83 92 12.6% -1.55 [-15.78, 12.68] Heterogeneity. Chil* = 0.08, df = 1 (P = 0.78); i* = 0% Fest for overall effect Z = 0.21 (P = 0.83) L8.5 6 mouths L8.5 6 mouths L8.5 6 mouths Fest for overall effect Z = 12.65 (P < 0.00001) L8.6 12 mouths Fest for overall effect Z = 12.65 (P < 0.00001) L8.6 12 mouths L9 yan 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Gu Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Tu Wellong 2020 135.68 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% C) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity. Chil* = 21.21, df = 10 (P < 0.00001); i* = 93% Fest for overall effect Z = 12.44.3 (P < 0.00001); i* = 93% Fest for overall effect Z = 12.121, df = 10 (P < 0.00001); i* = 95% Fest for overall effect Z = 12.57 (P < 0.00001) Fest for overall effect Z = 12.57 (P < 0.00001); i* = 95% Fest for overall effect Z = 12.57 (P < 0.00001); i* = 95% Fest for overall effect Z = 12.57 (P < 0.00001); i* = 95%			0.81)							
Subtotal (95% CI)										
Subtotal (95% CI) 80	1.8.3 10mg						-			
Section Sect	Xu Junping 2016	24.1	77.02	-	19.4	85.72	-			
Test for overall effect: Z = 0.36 (P = 0.72) 1.8.4 3 mouths 1.9.2 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.90 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 40.90 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] 1.9.2 40.89 66.9 68.9 68.9 68.9 68.9 68.9 68.9 6	Subtotal (95% CI)			80			80	4.0%	4.70 [-20.55, 29.95]	_
L8.4.3 mouths Hassan Ghobadi 2014										
Hassan Ghobadi 2014 3 148.5 23 -7 135.63 22 0.4% 10.00 [-73.04, 93.04] Jiu zheng 2017 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] Subhotal (95% Ct) 83 82 12.6% -1.55 [-15.78, 12.68] Heterogeneity, ChiP = 0.08, df = 1 (P = 0.78); iP = 0% Fest for overall effect Z = 0.21 (P = 0.83) 1.8.5 6 mouths Cheng shoubin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Subhotal (95% Ct) 75 75 16.3% 80.65 [68.15, 93.14] Heterogeneity, Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) 1.8.6 12 mouths He yan 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Gu Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Full Wellong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subhotal (95% Ct) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity, ChiP = 28.81, df = 2 (P < 0.00001); iP = 93% Fest for overall effect Z = 14.43 (P < 0.00001) Fest for overall effect Z = 20.57 (P < 0.00001) Fest for overall effect Z = 20.57 (P < 0.00001) Fest for overall effect Z = 20.57 (P < 0.00001) Fest for overall effect Z = 20.57 (P < 0.00001)	Test for overall effect. Z =	0.36 (P =	0.72)							
Justhering 2017 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] Subtotal (95% CI) 83 82 12.6% -1.55 [-15.78, 12.68] Heterogeneity: Chil* = 0.08, df = 1 (P = 0.78); P = 0% Fest for overall effect Z = 0.21 (P = 0.83) 1.8.5 6 mouths Cheng shoubin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Subtotal (95% CI) 75 75 16.3% 80.65 [68.15, 93.14] Subtotal (95% CI) 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Cu Wellong 2020 135.65 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% CI) 200 200 29.3% 68.70 [59.37, 78.04] Subtotal (95% CI) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity: Chil* = 211.21, df = 10 (P < 0.00001); P = 93% Fest for overall effect Z = 12.6.5 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fes	1.8.4 3 mouths									
Justhering 2017 66.9 40.37 60 68.8 40.37 60 12.2% -1.90 [-16.35, 12.55] Subtotal (95% CI) 83 82 12.6% -1.55 [-15.78, 12.68] Heterogeneity Chil* = 0.08, df = 1 (P = 0.78); P = 0% Fest for overall effect Z = 0.21 (P = 0.83) L8.5 6 mouths Subtotal (95% CI) 75 75 16.3% 80.65 [68.15, 93.14] Heterogeneity Not applicable Fest for overall effect Z = 12.65 (P < 0.00001) L8.6 12 moeths He yan 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Gu Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Full Wellong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% CI) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity Chil* = 28.81, df = 2 (P < 0.00001); P = 93% Fest for overall effect Z = 14.43 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95% Fest for overall effect Z = 20.57 (P < 0.00001); P = 95%	Hassan Ghobadi 2014	3	148.5	23	-7	135.63	22	0.4%	10.00 [-73.04, 93.04]	
Subtotal (95% CI) 83 82 12.6% -1.55 [-15.78, 12.68] Heterogeneity: Chilf = 0.08, df = 1 (P = 0.78); IP = 0% Fest for overall effect: Z = 0.21 (P = 0.83) L8.5 6 mouths Cheng shoubin 2015 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Heterogeneity: Not applicable Fest for overall effect: Z = 12.65 (P < 0.00001) L8.6 12 mouths Hey yan 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] Gu Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] For Wellong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% CI) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity: Chilf = 28.81, df = 2 (P < 0.00001); IP = 93% Fest for overall effect: Z = 14.43 (P < 0.00001) Fest for overall effect: Z = 20.57 (P < 0.00001); IP = 95% Fest for overall effect: Z = 20.57 (P < 0.00001); IP = 95% Fest for overall effect: Z = 20.57 (P < 0.00001); IP = 95%	Liu zheng 2017	66.9								-
Test for overall effect: Z = 0.21 (P = 0.83) L8.5 6 mouths Cheng shoubin 2015	Subtotal (95% CI)	-		83			82			•
Test for overall effect: Z = 0.21 (P = 0.83) L8.5 6 mouths Cheng shoubin 2015	Heterogeneity: Chi ² = 0.0	8, df = 1 (P = 0.78)	P = 09	6					
Cheng shoubin 2015										
Cheng shoubin 2015	1.8.5.6 mouths									
Subtotal (95% CI) 75 75 16.3% 80.65 [68.15, 93.14] Heterogeneity: Not applicable Fest for overall effect: Z = 12.65 (P < 0.00001) I.8.6 12 mouths He yan 2016 40.878 40.914 75 -39.77 37.06 75 16.3% 80.65 [68.15, 93.14] (u Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] (u Wellong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% CI) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity: Chi ² = 28.81, df = 2 (P < 0.00001); i ² = 93% Fest for overall effect: Z = 14.43 (P < 0.00001); i ² = 95% Fest for overall effect: Z = 20.57 (P < 0.00001); i ² = 95% Fest for overall effect: Z = 20.57 (P < 0.00001); i ² = 95%		40.878	40.914	75	-39.77	37.06	75	16.3%	80.65 [68.15, 93.14]	
Heterogeneity: Not applicable Fest for overall effect: Z = 12.65 (P < 0.00001) I.8.6 12 mouths He yan 2016		40.070	20.014		00.11	01.00				•
Test for overall effect: Z = 12.65 (P < 0.00001) 1.8.6 12 mouths He yan 2016		cable								
He yan 2016			< 0.0000	1)						
He yan 2016	1.8.6.12 morths									
Au Junping 2016 24.1 77.02 80 19.4 85.72 80 4.0% 4.70 [-20.55, 29.95] Au Weilong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Authorized (95% CI) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity: Chi ^P = 28.81, df = 2 (P < 0.00001); iP = 93% Fest for overall effect: Z = 14.43 (P < 0.00001) Heterogeneity: Chi ^P = 211.21, df = 10 (P < 0.00001); iP = 95% Fest for overall effect: Z = 20.57 (P < 0.00001) Features fe		40.979	40.914	76	-39.77	37.06	76	16 3%	80 65 68 15 92 141	-
Au Weilong 2020 135.66 40.639 45 60.15 41.13 45 8.9% 75.51 [58.62, 92.40] Subtotal (95% CI) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity: Chi ^a = 28.81, df = 2 (P < 0.00001); if = 93% Fest for overall effect: Z = 14.43 (P < 0.00001) Heterogeneity: Chi ^a = 211.21, df = 10 (P < 0.00001); if = 95% Fest for overall effect: Z = 20.57 (P < 0.00001)										
Subtotal (95% CI) 200 29.3% 68.70 [59.37, 78.04] Heterogeneity: Chi ^a = 28.81, df = 2 (P < 0.00001); if = 93% Fest for overall effect: Z = 14.43 (P < 0.00001) Fotal (95% CI) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity: Chi ^a = 211.21, df = 10 (P < 0.00001); if = 95% Fest for overall effect: Z = 20.57 (P < 0.00001)										
Heterogeneity: Chi ^a = 28.81, df = 2 (P < 0.00001); i ^a = 93% Fest for overall effect: Z = 14.43 (P < 0.00001) Fotal (95% CI) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity: Chi ^a = 211.21, df = 10 (P < 0.00001); i ^a = 95% Fest for overall effect: Z = 20.57 (P < 0.00001) Favours (experimental) Favours (controll		130.00	40.039		00.13	41.13				•
Fest for overall effect: Z = 14.43 (P < 0.00001) Fotal (95% CI) 641 639 100.0% 52.98 [47.93, 58.02] Heterogeneity: ChiP = 211.21, df = 10 (P < 0.00001); iP = 95% Fest for overall effect: Z = 20.57 (P < 0.00001) Favours (experimental) Favours (controll		91 45-2	/P < 0.00		- 03%		2.00	2000	221.0 [22/21] 10/24]	
Heterogeneity: Chi ^a = 211.21, df = 10 (P < 0.00001); i ^a = 95% Fest for overall effect: Z = 20.57 (P < 0.00001) Favours (experimental): Favours (control)			-		- 5576					
Heterogeneity: Chi ^a = 211.21, df = 10 (P < 0.00001); i ^a = 95% Fest for overall effect: Z = 20.57 (P < 0.00001) Favours (experimental): Favours (controll)	Tetal (DEV. CD.						630	100.00	E3 00 147 03 E0 031	•
Test for overall effect: Z = 20.57 (P < 0.00001) Favours (experimental) Favours (control)			10.00 - 0		· # - cc	~	033	100.0%	52.38 [41.93, 58.02]	
Favours lexiberimental Favours Icontrol), 1*= 95	%				-100 -50 0 50 100
estfor subdroup differences: Chi* = 101.22. df = 5 (P < 0.00001), P = 95.1%										Favours [experimental] Favours [control]
	est for subaroup differe	nces: Chi	= 101.2	2. df = :	5 (P < 0.)	00001). P	= 95.1	%		





Forest Plot with Leave-One-Out Analysis




a


b


Forest Plot with Leave-One-Out Analysis



Forest Plot with Leave-One-Out Analysis









d

e

Forest Plot with Leave-One-Out Analysis

Forest Plot with Leave-One-Out Analysis





h

Figure S1